Understanding the Cost and Funding of Gene Therapies

By Staff Writer

July 31, 2024

Introduction

Gene therapy is rapidly transforming the treatment landscape for rare diseases. With innovations like CAR T-cell therapy and CRISPR, patients have new therapeutic options. However, a significant challenge remains: the cost and funding of these treatments. Therefore, the question remains: who will bear the cost of these groundbreaking therapies?

The High Costs of Gene Therapies

Gene therapies, while groundbreaking, come with high price tags. The U.S. Food and Drug Administration (FDA) recently approved two cell-based gene therapies for sickle cell disease (SCD). These treatments, especially those involving CRISPR technology, offer hope to many. However, their cost raises questions about who should bear the financial burden.

Jay Newman, SVP of Commercial Development at Spark Therapeutics, highlighted this issue during the 2024 BIO International Convention. He noted that we are trying to administer 21st-century medicines within a 20th-century payment model. This sentiment resonated with many attendees, including caregivers, patients, and industry experts.

Patient Experiences and Financial Challenges

One caretaker, whose daughter Shelby has beta thalassemia, shared her story at the convention. Shelby participated in clinical trials for ZYNTEGLO, a gene therapy developed by bluebird bio. This one-time treatment significantly improved Shelby’s condition. However, securing insurance coverage was challenging. Initially, their insurer approved only one day of treatment, misunderstanding the therapy’s duration.

Fortunately, the Children’s Hospital of Philadelphia (CHOP) intervened, negotiating with the insurance company. This experience indicates the need for better understanding and coverage of gene therapies by insurers.

Value Over Price

Experts argue that the focus should be on the value of gene therapies, not just their cost. Tom Klima, Chief Operating and Commercial Officer at bluebird bio, emphasised the holistic costs associated with these treatments. One-time curative therapies can eradicate diseases, reducing long-term healthcare costs.

Klima also discussed outcomes-based agreements, which tie therapy costs to meaningful clinical outcomes. For example, bluebird bio offers rebates if their therapies do not achieve transfusion independence for patients. This approach aligns the cost of treatment with its real-world effectiveness.

State Health Plans and Policy Solutions

State health plans face the challenge of covering expensive gene therapies without bankrupting patients or their budgets. Stuart Portman, Executive Director at the Division of Medical Assistance Plans for Georgia, highlighted the need for alternative payment arrangements. These could be based on value or outcomes, but would require changes to existing policies.

Consistency and guarantees from federal entities are crucial. Portman stressed that states need assurance that federal policies around Medicaid will remain stable. Collaboration between federal and state governments, along with industry stakeholders, is essential to develop sustainable solutions.

Conclusion

The cost and funding of gene therapies present significant challenges, but also opportunities for innovation in healthcare financing. By focusing on the value of these treatments and exploring alternative payment models, we can ensure that patients have access to life-changing therapies. Collaboration between insurers, healthcare providers, and policymakers is key to navigating these financial complexities.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.